MD Anderson-led Phase I/II ARROW trial finds RET inhibitor to be well-tolerated with durable antitumor activity HOUSTON ― The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according […]
City of Houston Live
City of Katy katy
This player embeds official streams. If the live feed is offline, use the source link to view updates.
Browse previous videos
